How can a biotech startup increase greater than $1 billion over 4 plus years and say virtually nothing publicly alongside the best way? For Treeline Biosciences, the silence was strategic. Out of view of prying eyes, Treeline has quietly constructed a pipeline whose most superior applications are most cancers medicine addressing recognized targets however in new or doubtlessly higher methods. With a recent infusion of $200 million added to its funding haul and applications in early scientific improvement, Treeline is now pulling again the curtain on a few of its work.
The new financing is an extension of Treeline’s Collection A spherical of funding, the Watertown, Massachusetts-based firm mentioned Wednesday. It features a broad syndicate of well-known buyers that purchased into Treeline’s imaginative and prescient of reimagining the best way to finance and construct a special sort of drug discovery firm.
Rising biotechs are usually funded milestone to milestone, Treeline co-founder and CEO Josh Bilenker mentioned in a Wednesday weblog put up. Taking that strategy would lead Treeline to make selections to achieve the following milestone and preserve concentrate on a lead program. As a substitute, Treeline requested buyers to fund “repeated invention” that helps a number of however complementary applications. This strategy gave Treeline flexibility to completely vet applications earlier than progressing to the clinic and likewise to drop struggling ones.
“We’ve deserted applications as a result of we couldn’t discover good chemistry hits, as a result of we had unfavourable or blended information in efficacy fashions, as a result of there weren’t good efficacy fashions, as a result of we didn’t obtain ample (absorption, distribution, metabolism, and excretion), as a result of we had lingering issues round security, and since different firms bought there first with nice information,” Bilenker wrote. “Having the posh of shifting on from applications might be the best reward our funding mandate has given us.”
Treeline on Wednesday disclosed three most cancers applications, two internally found and one which was in-licensed. Internally found TLN-121 is a degrader of BCL6, a naturally occurring protein that sure lymphoma cells use to silence genes that may block their progress and survival. A Part 1 research is enrolling sufferers with B-cell and T-cell lymphomas.
The second disclosed inside Treeline program is TLN-372, an inhibitor of KRAS, a difficult-to-drug mutation that drives most cancers progress. Amgen’s Lumakras and Bristol Myers Squibb’s Krazati are each FDA-approved small molecule inhibitors of a selected KRAS mutation known as KRAS G12C. TLN-372 is a pan-KRAS small molecule inhibitor that blocks a number of KRAS variants. Treeline is conducting a Part 1 research enrolling sufferers with KRAS-altered stable tumors. The startup has competitors on this house. Different firms creating pan-KRAS inhibitors embrace Revolution MedicinesAstellas Pharma, Amgen, and BridgeBio Oncology Therapeutics.
The third disclosed Treeline program is TLN-254, which was licensed from Jiansu Hengrui Prescription drugs. Hengrui had superior this drug so far as Part 2 testing in refractory lymphoma. The small molecule inhibits EZH2, a protein that’s overexpressed or mutated in most cancers. Treeline is testing TLN-254 in a Part 1 research enrolling sufferers with peripheral and cutaneous T-cell lymphomas. A fourth program for an undisclosed goal is on monitor for an investigational new drug utility submitting in early 2026.
Treeline’s strategy to drug discovery brings laboratory and computational approaches collectively underneath the identical roof. Whereas different startups declare the identical, Bilenker mentioned Treeline is just not centered on a specific therapeutic space or a platform expertise. As a substitute, Treeline pursues fastidiously chosen targets with one of the best out there expertise, he mentioned.
Bilenker’s expertise consists of founding Loxo Oncology, which Eli Lilly acquired in 2019 for $8 billion. Treeline’s different co-founder is Chief Science Officer Jeff Engelman, the previous world head of oncology on the Novartis Institutes for BioMedical Analysis. Whereas the oncology expertise of each is mirrored within the Treeline pipeline, the startup says on its web site that most cancers analysis informs its work in different therapeutic areas. The corporate pursues these areas, comparable to autoimmune and neurological illness, “once we imagine now we have a singular benefit.”
Treeline fashioned in early 2021, based mostly in Watertown, based on Massachusetts company information. The startup revealed a bit of about itself in 2022 when it disclosed the addition of KKR to its investor syndicate with “a major capital dedication.” On the time, a securities submitting confirmed the corporate had raised greater than $261 million.
Thus far, Treeline mentioned it has raised about $1.1 billion complete. The startup’s buyers embrace AI Life Sciences, an affiliate of Entry Industries; Arch Enterprise Companions; OrbiMed; GV; KKR; accounts suggested by T. Rowe Value Associates; Ajax Well being/Zeus; Casdin Capital; Constancy Administration & Analysis Firm; Aisling Capital; Rock Springs Capital; and Exor.
Picture by Treeline Biosciences
